Stay updated on IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check4 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1 while the page remains a 403 error page.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study details. This indicates access restrictions or a server issue affecting the display of the study record.SummaryDifference19%

- Check46 days agoChange DetectedThe page revision label was bumped from v3.6.5 to v3.6.6, representing a minor update; no visible changes to the study information or layout are evident.SummaryDifference0.1%

- Check67 days agoChange DetectedThe page now shows revision v3.6.5, indicating a small platform update. The change represents an underlying system version bump rather than modifications to study text or results.SummaryDifference0.1%

- Check82 days agoChange DetectedThe site revision indicator was updated to v3.6.4, replacing the previous v3.6.3, indicating an update to the platform rather than any study content changes.SummaryDifference0.1%

- Check103 days agoChange DetectedThe page’s IPD Sharing revision indicator was updated from v3.6.2 to v3.6.3, reflecting a small documentation update.SummaryDifference0.1%

Stay in the know with updates to IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMGN853 + Pembrolizumab in Endometrial Cancer Clinical Trial page.